Journal: bioRxiv
Article Title: Single-Cell Protein Interactomes by the Proximity Network Assay
doi: 10.1101/2025.06.19.660329
Figure Lengend Snippet: (A) Workflow for functional characterization of CAR-T cells. CAR-T cells were either kept separate, or were mixed with CD19-positive Raji cells at an 1:1 E:T ratio. Cells were cocultured for either 4h or 24h, after which they were retrieved and fixed using 1 % PFA. Each sample was split into two duplicates and processed with the Proximity Network Assay according to the DP001 CAR Barcoded Antibody spike-in Proxiome kit (v1.00) manual. (B) The CAR-T cell population included both CD4⁺ and CD8⁺ subsets, with ∼40% of cells expressing the CD19 CAR transgene. (C) Proteins displaying positive colocalization (average score ≥0.1) with the CD19 CAR were plotted in a network (the CD19 CAR Proxiome). Positive colocalization scores for protein pairs other than the CD19 CAR have been grayed out for clarity. (D) Left: High-dimensional clustering based on protein abundance data for CAR-T cells alone, 4h cocultured cells, and 24h cocultured cells efficiently separating CD4, CD8 and Raji cells. Right: Cocultured T cells displayed increased levels of ICAM-1. (E) 3D visualization of a single CD8 T cell from the 24h cocultured sample. The cell displays a patchy ICAM-1 distribution where the patch colocalized with B cell markers like CD40, while anti-colocalizing with T cell marker CD8. (F) Illustration showcasing the process of trogocytosis, exchange of plasma membrane between cells, in CAR-T cells. (G) Quantification of tumor patches on the surface of CD8 + non-activated (CD25 - , PD-1 - ), activated (CD25 + , PD-1 - ) and exhausted (CD25 + , PD-1 + ) T cells. (H) An example of a CD8 T: Raji cell conjugate. The T cell (left) displays expression of T cell specific marker CD3e, while the Raji cell (right) expresses B cell marker CD40.
Article Snippet: Raji cells were fixed using 1% PFA, washed and analyzed using PNA, or stained for microscopy using either mouse anti-human CD40, mouse anti-human CD81 or mouse anti-human ICAM-1, followed by secondary staining using an anti-mouse AF647-conjugated monovalent nanobody (Chromotek).
Techniques: Functional Assay, Expressing, Quantitative Proteomics, Marker, Clinical Proteomics, Membrane